- Corrigendum: Testosterone Replacement Therapy and Cardiovascular Risk: A Review
-
Corona G, Rastrelli , Maseroli E, Sforza A, Maggi M
- KMID: 2349854
- World J Mens Health.
- 2016 Aug;34(2):154-154.
- doi: 10.5534/wjmh.2016.34.2.154
In published article by Corona G et al., an author's name was misspelled. -
- CITED
-
- Close
- SHARE
-
- Close
- Testosterone Replacement Therapy: Long-Term Safety and Efficacy
-
Corona G, Sforza A, Maggi M
- KMID: 2388442
- World J Mens Health.
- 2017 Aug;35(2):65-76.
- doi: 10.5534/wjmh.2017.35.2.65
Recent position statements and guidelines have raised the distinction between a true and false, age-related hypogonadism (HG) or late-onset hypogonadism (LOH). The former is the consequence of congenital or acquired... -
- CITED
-
- Close
- SHARE
-
- Close
- Testosterone Replacement Therapy and Cardiovascular Risk: A Review
-
Corona G G, Rastrelli , Maseroli E, Sforza A, Maggi M
- KMID: 2405141
- World J Mens Health.
- 2015 Dec;33(3):130-142.
- doi: 10.5534/wjmh.2015.33.3.130
Recent reports in the scientific and lay press have suggested that testosterone (T) replacement therapy (TRT) is likely to increase cardiovascular (CV) risk. In a final report released in 2015,... -
- CITED
-
- Close
- SHARE
-
- Close
- Risks and Benefits of Late Onset Hypogonadism Treatment: An Expert Opinion
-
Corona G, Vignozzi L, Sforza A, Maggi M
- KMID: 2320839
- World J Mens Health.
- 2013 Aug;31(2):103-125.
Late-onset hypogonadism (LOH) is a syndromic condition that has a well-recognized association with sexual and reproductive failure. LOH is frequently associated with chronic conditions including cardiovascular diseases (CVD), obesity, osteoporosis,... -
- CITED
-
- Close
- SHARE
-
- Close
- Testosterone Deficiency and Risk of Cognitive Disorders in Aging Males
-
Corona G, Guaraldi F, Rastrelli G, Sforza A, Maggi M
- KMID: 2509576
- World J Mens Health.
- 2021 Jan;39(1):9-18.
- doi: 10.5534/wjmh.200017
Cognitive impairment and dementia are predicted to undergo a dramatic increase in the following years with more than 131.5 million people being affected by 2030. Although vascular diseases play the... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Functional Hypogonadism Besides Pharmacological Substitution
-
Corona G, Rastrelli G, Morelli A, Sarchielli E, Cipriani S, Vignozzi L, Maggi M
- KMID: 2502995
- World J Mens Health.
- 2020 Jul;38(3):256-270.
- doi: 10.5534/wjmh.190061
A dichotomic distinction between “organic” and “functional” hypogonadism is emerging. The former is an irreversible condition due to congenital or “acquired” “organic” damage of the brain centers or of the... -
- CITED
-
- Close
- SHARE
-
- Close
- Consequences of Anabolic-Androgenic Steroid Abuse in Males; Sexual and Reproductive Perspective
-
Corona G, Rastrelli G, Marchiani S, Filippi S, Morelli A, Sarchielli E, Sforza A, Vignozzi L, Maggi M
- KMID: 2527316
- World J Mens Health.
- 2022 Apr;40(2):165-178.
- doi: 10.5534/wjmh.210021
The real epidemiology and the possible consequences of anabolic-androgenic steroids (AAS) use still represent a very tricky task due to the difficulties in the quantification and detection of these drugs.... -
- CITED
-
- Close
- SHARE
-
- Close
- Pudendal Nerve Neurolysis in Patients Afflicted With Pudendal Nerve Entrapment: A Systematic Review of Surgical Techniques and Their Efficacy
-
Giulioni C, Pirola GM, Maggi M, Pitoni L, Fuligni D, Beltrami M, Palantrani V, De Stefano V, Maurizi V, Castellani D, Galosi AB
- KMID: 2553888
- Int Neurourol J.
- 2024 Mar;28(1):11-21.
- doi: 10.5213/inj.2448010.005
To assess the effectiveness and safety of various techniques of pudendal nerve neurolysis (PNN) in patients with pudendal nerve entrapment (PNE). A comprehensive literature search was conducted on May 20th,... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
-
Corona G, Filippi S, Bianchi N, Dicuio M, Rastrelli G, Concetti S, Sforza A, Maggi M
- KMID: 2516699
- World J Mens Health.
- 2021 Jul;39(3):429-443.
- doi: 10.5534/wjmh.200109
Androgen deprivation therapy (ADT) is the gold standard treatment in patients with locally advanced or metastatic prostate cancer (PC). Emerging evidence has documented a tight association between ADT and body... -
- CITED
-
- Close
- SHARE
-
- Close
